The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

Condition:   Lower Risk MDS Per IPSS-R Intervention:   Drug: Luspatercept Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Beijing Health Alliance Charitable Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials